Retinalyze, LLC Signs Licensing Agreement for Vision Plan Reimbursement
20 Junio 2012 - 7:46AM
Business Wire
Retinalize, LLC is pleased to announce that it has signed an
agreement to begin using the Retinalytics SVMTM analysis technology
for Vision Care Direct and associated vision health and wellness
plans. Retinalize, LLC is a 50%/50% joint venture between Health
Discovery Corporation (OTCBB: HDVY), a molecular
diagnostics leader in the use of patent protected advanced
mathematical techniques for personalized medicine, and Doctors
Optimal Formula LLC, a physician exclusive anti-aging, health
and wellness company.
Retinalytics SVMTM is to be used for Vision Care Direct’s Vision
Plans and corresponding Independent Physician Associations (IPA)
systems which currently have well over 3 million patient lives
covered. In addition to the current Retinalytics SVMTM module for
macular degeneration, Retinalize, LLC is currently completing a
module for Alzheimer’s detection and beginning development on a
module for Diabetic Retinopathy. Vision Care Direct intends to
utilize these multiple modules to create wellness plans using
Retinalytics SVMTM to assist physicians as their primary screening
tool.
Reid Nelson, President, Vision Care Direct, states, “Vision Care
Direct (VCD) and the doctors of the Independent Physician
Associations (IPA) are excited about reaching an agreement with
Retinalize, LLC to utilize their Retinalytics SVMTM analysis
technology. VCD is pleased to be adding Retinalytics SVMTM
technology to its product offerings and rolling out a new product
that embeds Retinalytics SVMTM as a covered benefit. This SVM
technology and the new Retinalytics SVMTM products come at a time
when health plans, governments and employers are discovering that
comprehensive eye exams can saves lives and lower health care
costs. The SVM technology could allow comprehensive eye exams to
become a fundamental building block of any health care
regimen.”
“The incorporation of Retinalytics SVMTM into Vision Care
Direct’s Vision Plan, will give us national exposure to patients
and providers alike,” said Howard Loff, M.D., CEO of Retinalyze,
LLC. “With Retinalytics SVMTM now becoming a reimbursed covered
benefit, we expect near 100% utilization by these newly covered
patients.”
Ronald Fiegel, OD, President of the Kansas IPA, Vision Care
Plus, Inc., notes, “In addition to our Vision Care Direct Members,
Vision Care Plus is actively exploring opportunities that will
allow our providers to utilize Retinalytics SVMTM technology in
caring for the approximately 500,000 lives we have under primary
eye care contracts throughout Kansas. We also see this as a
valuable contributor to the enhanced well care and cost savings
needed to make Accountable Care Organization's and Medical Homes a
reality for the millions of patients with life altering diseases
such Diabetes and Alzheimer's.”
Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery
Corporation, added, “We are very excited to see HDC's SVM
technology being incorporated as a reimbursed test procedure within
these vision plans. We are proud of the fact that Retinalytics
SVMTM could set a new standard of care by assisting physicians in
the eye care industry.”
Eye Doctors and patients interested in learning more about
Vision Care Direct, please visit www.visioncaredirect.com.
About Doctors Optimal Formula LLC
Having been founded by medical doctors, Doctors Optimal Formula
prides itself on providing the best, scientifically formulated
nutritional supplements and anti-aging skin care available today!
Focusing on maintaining and improving the health and well-being of
our customers, Doctors Optimal Formula has become vertically
integrated to encompass all aspects of healthcare, such as Vision
Care Plans, Prescription Pharmacy Plans and a physician provider
network of over 10,000 physicians. For more information, visit
www.DoctorsOptimalFormula.com.
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company
that uses advanced mathematical techniques to analyze large amounts
of data to uncover patterns that might otherwise be undetectable.
It operates primarily in the emerging field of personalized
medicine where such tools are critical to scientific discovery. Its
primary business consists of licensing its intellectual property
and developing its own product line of biomarker-based diagnostic
tests that include human genes and genetic variations, as well as
gene, protein, and metabolic expression differences and image
analysis in digital pathology and radiology. For more information,
see www.healthdiscoverycorp.com.
Forward-Looking Statements
This document contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
the accuracy of which is necessarily subject to risks and
uncertainties, including, without limitation, statements regarding
future performance, opportunities and investments, and anticipated
results in general. From time to time the Company may make other
forward-looking statements in relation to other matters, including
without limitation, commercialization plans and strategic
partnerships. Actual results may differ materially due to a variety
of factors, including, among other things, the acceptance of our
approach to applying mathematics, computer science and physics into
the disciplines of biology, organic chemistry and medicine and our
products and technologies associated with those approaches, the
ability to develop and commercialize new drugs, therapies or other
products based on our approaches, and other factors set forth from
time to time in the Company’s Securities and Exchange Commission
filings.
All forward-looking statements and cautionary statements
included in this document are made as of the date hereof based on
information available to the Company as of the date hereof, and the
Company assumes no obligation to update any forward-looking
statement or cautionary statement.
Health Discovery (CE) (USOTC:HDVY)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Health Discovery (CE) (USOTC:HDVY)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024